MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies

SE Ahmadi, S Rahimi, B Zarandi, R Chegeni… - Journal of hematology & …, 2021 - Springer
MYC oncogene is a transcription factor with a wide array of functions affecting cellular
activities such as cell cycle, apoptosis, DNA damage response, and hematopoiesis. Due to …

Myc and cell cycle control

G Bretones, MD Delgado, J León - Biochimica et Biophysica Acta (BBA) …, 2015 - Elsevier
Soon after the discovery of the Myc gene (c-Myc), it became clear that Myc expression levels
tightly correlate to cell proliferation. The entry in cell cycle of quiescent cells upon Myc …

Myc roles in hematopoiesis and leukemia

MD Delgado, J León - Genes & cancer, 2010 - journals.sagepub.com
Hematopoiesis is a process capable of generating millions of cells every second, as
distributed in many cell types. The process is regulated by a number of transcription factors …

MYC interacts with the G9a histone methyltransferase to drive transcriptional repression and tumorigenesis

WB Tu, YJ Shiah, C Lourenco, PJ Mullen, D Dingar… - Cancer cell, 2018 - cell.com
MYC is an oncogenic driver that regulates transcriptional activation and repression.
Surprisingly, mechanisms by which MYC promotes malignant transformation remain …

MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma

AR Grayson, EM Walsh, MJ Cameron, J Godec… - Oncogene, 2014 - nature.com
NUT midline carcinoma (NMC) is an aggressive type of squamous cell carcinoma that is
defined by the presence of BRD-NUT fusion oncogenes, which encode chimeric proteins …

BPTF is required for c-MYC transcriptional activity and in vivo tumorigenesis

L Richart, E Carrillo-de Santa Pau… - Nature …, 2016 - nature.com
Abstract c-MYC oncogene is deregulated in most human tumours. Histone marks associated
with transcriptionally active genes define high-affinity c-MYC targets. The mechanisms …

Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells

FO Enane, Y Saunthararajah, M Korc - Cell death & disease, 2018 - nature.com
Chemotherapeutic drugs have a common intent to activate apoptosis in tumor cells.
However, master regulators of apoptosis (eg, p53, p16/CDKN2A) are frequently genetically …

Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis

D Diolaiti, L McFerrin, PA Carroll… - Biochimica et Biophysica …, 2015 - Elsevier
The transcription factor MYC and its related family members MYCN and MYCL have been
implicated in the etiology of a wide spectrum of human cancers. Compared to other …

Immortalization of erythroblasts by c-MYC and BCL-XL enables large-scale erythrocyte production from human pluripotent stem cells

S Hirose, N Takayama, S Nakamura, K Nagasawa… - Stem cell reports, 2013 - cell.com
The lack of knowledge about the mechanism of erythrocyte biogenesis through self-
replication makes the in vitro generation of large quantities of cells difficult. We show that …

Myc stimulates cell cycle progression through the activation of Cdk1 and phosphorylation of p27

L García-Gutiérrez, G Bretones, E Molina, I Arechaga… - Scientific reports, 2019 - nature.com
Cell cycle stimulation is a major transforming mechanism of Myc oncoprotein. This is
achieved through at least three concomitant mechanisms: upregulation of cyclins and Cdks …